Profound Medical's prostate cancer treatment

October 2, 2009 by MassDevice

The Toronto-based firm is developing an MRI-guided ultrasound device to treat prostate cancer.

Profound Medical's prostate cancer treatment

MassDevice is liveblogging the MassMEDIC 11th Annual Medtech Investors Conference. We're talking to the officers and executives of some of the hottest under-the-radar medical device firms around, finding out how and why their technologies will separate them from the pack.

Profound Medical Inc., Toronto, Ont.

Profound Medical is developing an interventional, MRI-guided, trans-urethral ultrasound device to treat prostate cancer.

Paul Chipperton, COO/CEO
Cameron Mahon, VP of Engineering & Product Development
Clinical Advisory Board
Laurence Klotz, Mukesh Harisinghani, Eric Klein, Michael Marberger

There are major quality-of-life issues with all existing treatments for prostate cancer, with unacceptable levels of postoperative impotence and incontinence. Profound’s interventional MRI-guided, trans-urethral ultrasound medical device provides the least invasive treatment, in the shortest possible time, as an out-patient procedure, offering incomparable accuracy and precision.

Further, the precision of this device offers surgeons and patients unparalleled treatment planning options, ranging from a whole prostate down to a small focal region. This accuracy of treatment is critically important for sparing structures related to potency, and the continence of the urethra and rectum.